R348 Ophthalmic Solution, 0.2%
C-932348-004
Phase 2 small_molecule completed
Quick answer
R348 Ophthalmic Solution, 0.2% for Chronic Graft-versus-host Disease is a Phase 2 program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RIGEL PHARMACEUTICALS INC
- Indication
- Chronic Graft-versus-host Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed